Last reviewed · How we verify

NCT03892824: CAPTURE2

Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants

Active, enrolled NA Last updated 20 February 2025
What this trial tests

NA trial testing Vine™ Embolic Protection System in Atrial Fibrillation in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
15 April 2019
Primary endpoint
24 October 2024
24 October 2027

Quick facts

Lead sponsorJavelin Medical
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment100
Start date15 April 2019
Primary completion24 October 2024
Estimated completion24 October 2027
Sites17 locations across Czechia, Poland, Belgium, Israel, Hungary, Greece, Germany, Spain

Drugs / interventions tested

Conditions studied

Sponsor

Javelin Medical

Who can join

50 and older, any sex, with Atrial Fibrillation or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety and performance of the Vine™ Embolic Protection System (embolic filtering device) in atrial fibrillation (AF) patients on top of oral anticoagulants (OAC), and remain at high risk for stroke recurrence. All patients will receive bilateral implants in the common carotid arteries

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Permanent Bilateral Carotid Filters for Stroke Prevention in Atrial Fibrillation.
    De Potter T, Yodfat O, Shinar G, Neta A, et al · · 2020 · cited 6× · PMID 32910288 · DOI 10.1007/s11886-020-01388-w

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Javelin Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03892824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing